Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...

President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with ...

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped ...

You’ve probably heard of Ozempic, Wegovy, Zepbound, and Mounjaro. But if your algorithm serves up wellness and fitness ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.